Demeclocycline: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
__NOTOC__
|authorTag=
{{SI}}
{{CMG}}


==Overview==


<!--Overview-->
'''Demeclocycline''' (marketed as Declomycin, Declostatin, and Ledermycin) is a [[tetracycline antibiotic]] derived from a strain of ''[[Streptomyces aureofaciens]]''.


|genericName=
==Uses==
It is officially indicated for the treatment of various types of [[bacteria]]l [[infection]]s.<ref name="urlDailyMed: About DailyMed">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=673 |title=DailyMed: About DailyMed |format= |work= |accessdate=2008-12-20}}</ref> It is used as an antibiotic in the treatment of [[Lyme disease]], [[Acne vulgaris|acne]], and [[bronchitis]].  Resistance, though, is gradually becoming more common, and demeclocycline is now rarely used for infections.


It is widely used (though [[off-label use|off-label]] in many countries) in the treatment of [[hyponatremia]] (low blood [[sodium]] concentration) due to the [[syndrome of inappropriate antidiuretic hormone]] (SIADH) when fluid restriction alone has been ineffective.<ref name=Goh>{{cite journal |author=Goh KP |title=Management of hyponatremia |journal=[[American Family Physician]] |volume=69 |issue=10 |pages=2387–94 |date=May 2004 |pmid=15168958 |url=http://www.aafp.org/afp/20040515/2387.html}}</ref> Physiologically, this works by reducing the responsiveness of the collecting tubule cells to ADH.


|aOrAn=
The use in SIADH actually relies on a side effect; demeclocycline induces [[diabetes insipidus|nephrogenic diabetes insipidus]] (dehydration due to the inability to concentrate urine).<ref name=Goh/> The use of demeclocycline in SIADH was first reported in 1975,<ref name="Cherrill">{{cite journal |author=Cherrill DA, Stote RM, Birge JR, Singer I |title=Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion |journal=[[Annals of Internal Medicine]] |volume=83 |issue=5 |pages=654–6 |date=November 1975 |pmid=173218 |doi=10.7326/0003-4819-83-5-654}}</ref> and, in 1978, a larger study found it to be more effective and better tolerated than [[lithium carbonate]], the only available treatment at the time.<ref name=Tolstoi>{{cite journal |author=Tolstoi LG |title=A brief review of drug-induced syndrome of inappropriate secretion of antidiuretic hormone |journal=[[Medscape|Medscape Pharmacotherapy]] |volume=4 |issue=1 |year=2002 |url=http://www.medscape.com/viewarticle/420687_print}} Retrieved on October 27, 2008.</ref> Demeclocycline has since been the drug of choice for treating SIADH, although it may be superseded as [[vasopressin receptor antagonist]]s, such as [[tolvaptan]], become available.<ref name=Tolstoi/>
a


|drugClass=
==Contraindications==
Like [[tetracycline antibiotics|other tetracyclines]], demeclocycline is contraindicated in children and pregnant or nursing women. All members of this class interfere with [[bone]] development and may discolour [[tooth|teeth]].


==Side effects and interactions==
These are similar to those of other tetracyclines. Skin reactions with sunlight have been reported. Demeclocycline is unique in that it is the only tetracycline known to cause nephrogenic diabetes insipidus.


|indication=
Tetracyclines bind to [[cation]]s, such as [[calcium]], [[iron]] (when given orally), and [[magnesium]], rendering them insoluble and inabsorbable for the gastrointestinal tract. Demeclocycline should not be taken with food (particularly milk and other dairy products) or [[antacid]]s.


==Mechanism of action==
As with related tetracycline antibiotics, demeclocycline acts by binding to the [[30S]] ribosomal subunit to inhibit binding of aminoacyl tRNA which impairs [[protein synthesis]] by bacteria. It is [[bacteriostatic]] (it impairs bacterial growth, but does not kill bacteria directly).


|hasBlackBoxWarning=
It is not completely understood why demeclocycline impairs the action of [[antidiuretic hormone]], but is thought to block the binding of the hormone from its [[receptor (biochemistry)|receptor]].<ref>{{cite journal |doi=10.1056/NEJM197510302931809 |author=De Troyer A, Demanet JC |title=Correction of antidiuresis by demeclocycline |journal=N Engl J Med |volume=293 |issue=18 |pages=915–8 |year=1975 |pmid=170519}}</ref>
Yes


|adverseReactions=
==References==
{{Reflist|2}}


 
[[Category:Tetracycline antibiotics]]
<!--Black Box Warning-->
[[Category:Organochlorides]]
 
[[Category:Amides]]
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>Content
 
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
======Central Nervous System======
 
 
 
======Cardiovascular======
 
 
 
======Respiratory======
 
 
 
======Gastrointestinal======
 
 
 
======Hypersensitivity======
 
 
 
======Miscellaneous======
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
======Central Nervous System======
 
 
 
======Cardiovascular======
 
 
 
======Respiratory======
 
 
 
======Gastrointestinal======
 
 
 
======Hypersensitivity======
 
 
 
======Miscellaneous======
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
Oral
 
Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
=====Condition1=====
 
Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
Description
 
====Management====
 
Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drugbox2-->
 
|drugBox=
 
<!--Mechanism of Action-->
 
|mechAction=
 
<!--Structure-->
 
|structure=
 
There is limited information regarding <i>Structure</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacodynamics-->
 
|PD=
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
 
<!--Pharmacokinetics-->
 
|PK=
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
=====Condition1=====
 
Description
 
<!--How Supplied-->
 
|howSupplied=
 
<!--Patient Counseling Information-->
 
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
 
|alcohol=
Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
 
|brandNames=
 
<!--Look-Alike Drug Names-->
 
|lookAlike=
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
 
<!--Drug Shortage Status-->
 
|drugShortage=
}}
 
<!--Pill Image-->
 
{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}
 
<!--Label Display Image-->
 
{{LabelImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
}}
 
<!--Category-->
 
[[Category:Cardiovascular Drugs]]
[[Category:Drug]]

Latest revision as of 23:30, 30 June 2014

WikiDoc Resources for Demeclocycline

Articles

Most recent articles on Demeclocycline

Most cited articles on Demeclocycline

Review articles on Demeclocycline

Articles on Demeclocycline in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Demeclocycline

Images of Demeclocycline

Photos of Demeclocycline

Podcasts & MP3s on Demeclocycline

Videos on Demeclocycline

Evidence Based Medicine

Cochrane Collaboration on Demeclocycline

Bandolier on Demeclocycline

TRIP on Demeclocycline

Clinical Trials

Ongoing Trials on Demeclocycline at Clinical Trials.gov

Trial results on Demeclocycline

Clinical Trials on Demeclocycline at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Demeclocycline

NICE Guidance on Demeclocycline

NHS PRODIGY Guidance

FDA on Demeclocycline

CDC on Demeclocycline

Books

Books on Demeclocycline

News

Demeclocycline in the news

Be alerted to news on Demeclocycline

News trends on Demeclocycline

Commentary

Blogs on Demeclocycline

Definitions

Definitions of Demeclocycline

Patient Resources / Community

Patient resources on Demeclocycline

Discussion groups on Demeclocycline

Patient Handouts on Demeclocycline

Directions to Hospitals Treating Demeclocycline

Risk calculators and risk factors for Demeclocycline

Healthcare Provider Resources

Symptoms of Demeclocycline

Causes & Risk Factors for Demeclocycline

Diagnostic studies for Demeclocycline

Treatment of Demeclocycline

Continuing Medical Education (CME)

CME Programs on Demeclocycline

International

Demeclocycline en Espanol

Demeclocycline en Francais

Business

Demeclocycline in the Marketplace

Patents on Demeclocycline

Experimental / Informatics

List of terms related to Demeclocycline

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Demeclocycline (marketed as Declomycin, Declostatin, and Ledermycin) is a tetracycline antibiotic derived from a strain of Streptomyces aureofaciens.

Uses

It is officially indicated for the treatment of various types of bacterial infections.[1] It is used as an antibiotic in the treatment of Lyme disease, acne, and bronchitis. Resistance, though, is gradually becoming more common, and demeclocycline is now rarely used for infections.

It is widely used (though off-label in many countries) in the treatment of hyponatremia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) when fluid restriction alone has been ineffective.[2] Physiologically, this works by reducing the responsiveness of the collecting tubule cells to ADH.

The use in SIADH actually relies on a side effect; demeclocycline induces nephrogenic diabetes insipidus (dehydration due to the inability to concentrate urine).[2] The use of demeclocycline in SIADH was first reported in 1975,[3] and, in 1978, a larger study found it to be more effective and better tolerated than lithium carbonate, the only available treatment at the time.[4] Demeclocycline has since been the drug of choice for treating SIADH, although it may be superseded as vasopressin receptor antagonists, such as tolvaptan, become available.[4]

Contraindications

Like other tetracyclines, demeclocycline is contraindicated in children and pregnant or nursing women. All members of this class interfere with bone development and may discolour teeth.

Side effects and interactions

These are similar to those of other tetracyclines. Skin reactions with sunlight have been reported. Demeclocycline is unique in that it is the only tetracycline known to cause nephrogenic diabetes insipidus.

Tetracyclines bind to cations, such as calcium, iron (when given orally), and magnesium, rendering them insoluble and inabsorbable for the gastrointestinal tract. Demeclocycline should not be taken with food (particularly milk and other dairy products) or antacids.

Mechanism of action

As with related tetracycline antibiotics, demeclocycline acts by binding to the 30S ribosomal subunit to inhibit binding of aminoacyl tRNA which impairs protein synthesis by bacteria. It is bacteriostatic (it impairs bacterial growth, but does not kill bacteria directly).

It is not completely understood why demeclocycline impairs the action of antidiuretic hormone, but is thought to block the binding of the hormone from its receptor.[5]

References

  1. "DailyMed: About DailyMed". Retrieved 2008-12-20.
  2. 2.0 2.1 Goh KP (May 2004). "Management of hyponatremia". American Family Physician. 69 (10): 2387–94. PMID 15168958.
  3. Cherrill DA, Stote RM, Birge JR, Singer I (November 1975). "Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion". Annals of Internal Medicine. 83 (5): 654–6. doi:10.7326/0003-4819-83-5-654. PMID 173218.
  4. 4.0 4.1 Tolstoi LG (2002). "A brief review of drug-induced syndrome of inappropriate secretion of antidiuretic hormone". Medscape Pharmacotherapy. 4 (1). Retrieved on October 27, 2008.
  5. De Troyer A, Demanet JC (1975). "Correction of antidiuresis by demeclocycline". N Engl J Med. 293 (18): 915–8. doi:10.1056/NEJM197510302931809. PMID 170519.